Avita Medical Inc. (ASX:AVH)


right-arrow Created with Sketch. 0 (0%)
MCAP $366.9M
Last trade 09.42am 28/01/2022 20mins delayed

Latest Announcements

25/01/2022AVHAvita Medical Inc.
25/01/2022AVHAvita Medical Inc.
12/01/2022AVHAvita Medical Inc.
12/01/2022AVHAvita Medical Inc.
11/01/2022AVHAvita Medical Inc.
11/01/2022 Price SensitivePSAVHAvita Medical Inc.
07/01/2022AVHAvita Medical Inc.
07/01/2022AVHAvita Medical Inc.

Company Overview

AVITA Medical, Inc. is a regenerative medicine company. The Company is engaged in developing and commercializing a technology platform, which enables point-of-care autologous skin restoration for multiple unmet needs. It provides treatment solutions derived from the regenerative properties of a patient’s own skin. Its RECELL Autologous Cell Harvesting System (RECELL) enables clinicians to prepare Spray-On Skin Cells, an autologous skin cell suspension, which is sprayed onto the patient to regenerate natural healthy skin. The RECELL System is a single use disposable, stand-alone, battery operated, autologous cell harvesting device containing enzymatic and buffer solutions, sterile surgical instruments, and actuators to achieve the disaggregation and delivery of skin cells. The platform technology of the RECELL System allows for the preparation and delivery of Spray-On Skin Cells, an autologous cellular suspension comprised of the patient’s own skin cells.

AVH in the news

AVITA Medical (AVH) reports its preclinical data establishes proof of concept in…
AVITA Medical (AVH) raked in $7 million in revenue during the first…
The US Food and Drug Administration (FDA) approves change to Avita Medical’s…
Avita Medical (AVH) is included in the Russell 3000 Index as part…

Search Previous Announcements